v3.26.1
Condensed Consolidated Statements of Operations and Comprehensive Loss - USD ($)
3 Months Ended
Mar. 31, 2026
Mar. 31, 2025
Condensed Consolidated Statements of Operations and Comprehensive Loss    
Grant revenue   $ 162,463
Operating expenses:    
Research and development $ 1,611,167 2,483,066
General and administrative 1,819,245 1,764,979
Total operating expenses 3,430,412 4,248,045
Loss from operations (3,430,412) (4,085,582)
Other income (expense):    
Interest income, net 134,784 204,726
Foreign currency gain (loss) 7,711 (51,803)
Total other income 142,495 152,923
Net loss (3,287,917) (3,932,659)
Other comprehensive income:    
Foreign currency translation 9,014 643
Total comprehensive loss $ (3,278,903) $ (3,932,016)
Net loss per share attributable to common stockholders, basic (in dollars per share) $ (0.22) $ (0.66)
Net loss per share attributable to common stockholders, diluted (in dollars per share) $ (0.22) $ (0.66)
Weighted-average common shares outstanding, basic (in shares) 14,685,448 5,993,866
Weighted-average common shares outstanding, diluted (in shares) 14,685,448 5,993,866